Drug intelligence / Profile preview

SGB-BS03

Development stage: Preclinical
Lead developer: Sanegene Bio
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

SGB-BS03 is an RNA interference (RNAi) therapeutic candidate being developed by Suzhou Shengyin Biopharmaceutical (SanegeneBio) for the treatment of metabolic-associated steatohepatitis (MASH). Utilizing SanegeneBio's proprietary RNAi platform, the drug is designed to silence a specific, currently undisclosed gene target involved in the pathogenesis of MASH, a progressive form of liver disease characterized by inflammation and fibrosis. As of mid-2024, the program is in the Lead Identification (Lead ID) stage of preclinical development, focusing on optimizing the siRNA sequence for potent and durable gene silencing in the liver.

Beyond the preview

Go deeper on SGB-BS03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGB-BS03.

Explore the full profile